BMY sees reason for optimism over the final half of the year.
There is no thought of selling here and now, even with politicized pressure on the industry.
Biotechnology is always high risk but the right plays move unlike anything else.
Investors are anxious to grab the next penny stock that may be poised to jump on the mind-blowing bubble. Here they are.
Let's review the charts and indicators.
Our fate is in the hands of a few dozen companies with a dizzying array of clinical trials, and whoever gets there first is gonna make a fortune.
The question is when to buy and what to risk.
Oxford University, along with Britain's AstraZeneca, published promising data from an early stage trial of a key coronavirus vaccine study Monday in London.
BHVN has made a relatively big advance since April and a period of consolidation or sideways price action is probably likely at this time.
One would need to use covered calls to initiate positions that provide a solid amount of downside protection.